Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADORA: Anticoagulant Cessation After aPL Loss in Thrombotic APS
NCT07875153Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in antiphospholipid syndrome (APS) and thrombosis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: First Recurrent Of Thrombotic Event at 48 months. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
antiphospholipid syndrome (APS)thrombosis
Beyond the preview
Go deeper on NCT07875153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875153.